Trump Exempts Generic Drugs from Proposed Pharmaceutical Tariffs

Donald Trump decided to exempt generic medications from proposed 100% tariffs, scaling back a national-security pharmaceutical trade investigation led by the United States Department of Commerce. The decision reverses an earlier campaign pledge to restore the production of essential generic medicines to the United States.

While the administration continues to target branded or patented pharmaceutical products—threatening 100% tariffs unless companies build manufacturing plants in America—officials determined that taxing generics would be counterproductive. The United States Domestic Policy Council and other healthcare advisers argued that tariffs on generics, which account for approximately 90% of U.S. prescriptions, would cause price increases and drug shortages.

The policy shift significantly impacts India, which provides 47% of all generic prescriptions filled in U.S. pharmacies. Following the news, shares of Indian pharmaceutical companies surged. Although some Commerce Department officials maintained that tariffs were necessary to reduce foreign dependence after pandemic-era disruptions, the administration is now exploring alternative measures to encourage domestic production, including federal grants and loans.

U.S. Trade Representative Jamieson Greer stated the administration is evaluating the best way to deploy economic tools regarding generics, many of which currently enter the U.S. tariff-free.